DUBLIN--(BUSINESS WIRE)--The "HPV Testing and Pap Test Market by Test Type (HPV Testing (Follow-Up HPV Testing, Co-Testing, Primary HPV Testing), PAP Test), End User (Laboratories, Hospitals, Physician's Offices & Clinics), Region - Global Forecast to 2027" report has been added to ResearchAndMarkets.com's offering.
The global HPV testing and Pap test market is projected to reach USD 9.2 billion by 2027 from USD 4.9 billion in 2022, at a CAGR of 13.2% during the forecast period.
The HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market, by test type, during the forecast period
The HPV testing and Pap test market is segmented into HPV testing and Pap test. In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market. Increase in number of product approval and increased focus on reducing cancer cases are major factor contributing to the growth of this segment.
The cervical cancer screening segment accounted for the highest growth rate in the HPV testing and Pap test market, by application, during the forecast period
The HPV testing and Pap test market is segmented into cervical cancer screening and vaginal cancer screening. In 2021, HPV testing segment accounted for the highest growth rate in the HPV testing and Pap test market. Increasing funding for the prevention of cervical cancer are major factors contributing to the growth of this segment.
The hospitals segment accounted for the highest growth rate in the HPV testing and Pap test market, by end user, during the forecast period
The HPV testing and Pap test market is segmented into laboratories, hospitals and physician's offices & clinics based on end user. In 2021, the hospitals segment accounted for the highest growth rate in the HPV testing and Pap test market. Emerging markets offering lucrative growth opportunities are major factors contributing to the growth of this segment.
Asia Pacific: The fastest-growing region in HPV testing and Pap test market
The global HPV testing and Pap test market is segmented into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. The Asia Pacific region is projected to register the highest CAGR during the forecast period. Increasing number of conferences focused on creating awareness of cervical cancer is driving the growth of the HPV testing and Pap test market in this region.
Market Dynamics
Drivers
- Rising HPV Cases and Subsequent Increase in Cervical Cancer
- Growing Awareness of Cervical Cancer Screening Programs
- Increasing R&D Funding Initiatives on Cervical Cancer Prevention
Restraints
- Growing Awareness of HPV Vaccination
Opportunities
- Regulatory Guidelines for Cervical Cancer Screening
- Innovative Improvements in HPV Tests
- Introduction of HPV Primary Screening Tests
- Technological Improvements in HPV Tests
Challenges
- Uncertain Reimbursement Scenario
- Stringent Regulatory & Legal Requirements
- Operational Barriers
Companies Mentioned
- Abbott Laboratories
- Arbor Vita Corporation
- Becton, Dickinson and Company
- Dalrada Corporation
- Everlywell Inc.
- Femasys, Inc.
- Hologic, Inc.
- Jiangsu Mole Bioscience Co. Ltd.
- Mylab Discovery Solutions Pvt. Ltd.
- Neodiagnostix
- Nurx Inc.
- Qiagen N.V.
- Quest Diagnostics
- Roche Diagnostics
- Sansure Biotech Inc.
- Seegene, Inc.
For more information about this report visit https://www.researchandmarkets.com/r/p5nywh
